MOUNTAIN LAKES, N.J., March 24, 2026 /PRNewswire/ — LiviWell, a women’s health company dedicated to developing innovative solutions for intimate health, today announced that the U.S. Food and Drug Administration (FDA) has cleared Livi, a first-of-its-kind device designed to support vaginal health by absorbing semen and other post-intercourse fluids.
CINCINNATI, March 18, 2026 /PRNewswire/ — Mammotome, a Danaher company, announces FDA Clearance of two innovations for MR-guided breast biopsy: the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System – the industry’s first solution designed to be positioned in the MRI scanner room at the patient’s side – and the HydroMARK™ Plus Breast Biopsy Site Marker for MR, engineered for exclusive use with the Mammotome Prima™ system universal targeting set. Following a successful debut of the Mammotome Prima™ MR system in Europe, both products will be introduced to U.S. clinicians at the 2026 Society of Breast Imaging (SBI) Symposium. By bringing the device directly into the scanner room, the Mammotome Prima™ MR system enhances clinician coordination, streamlines communication, and helps maintain consistent focus on the patient throughout the procedure.
From cobblers to smoothies, dark sweet cherries show up in plenty of recipes, and scientists say the crimson-colored fruit may contain compounds that could help fight an aggressive type of breast cancer.
Researchers at Mass General Brigham have developed a series of artificial intelligence (AI) tools that uses machine learning to identify individuals who may be at risk for intimate partner violence (IPV) using information from their electronic medical records (EMRs).
The scanner reconstructs 3D tomographic images by utilising both reflection-mode and transmission-mode ultrasound data.
An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
Researchers from the University of California San Diego have found that a novel blood-based biomarker can predict a woman’s risk of developing dementia as many as 25 years before symptoms appear.
Scientists at Sanford Burnham Prebys and the University of California San Diego have published findings in Cell Reports demonstrating a treatment approach in mice that allowed more tumor-fighting cells to approach tumors.
OSLO, Norway, March 3, 2026 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA), enabling commercial launch in China.
TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment.